-
Why UBS says Q4 is eventful for SMID oncology stocks
-
CMS grants reimbursement status for Telix's Gozellix prostate imaging agent
-
Citi Opens 90-Day Upside Catalyst Watch on Telix Pharmaceuticals (TLX)
-
Citi Starts Telix Pharmaceuticals Ltd (TLX) at Buy
-
Telix Pharmaceuticals Ltd (TLX) PT Lowered to $20 at H.C. Wainwright
-
JPMorgan Downgrades Telix Pharmaceuticals Ltd (TLX) to Neutral
-
H.C. Wainwright Starts Telix Pharmaceuticals Ltd (TLX) at Buy
-
Telix Pharmaceuticals (TLX) Appoints Paul Schaffer as CTO
-
Telix Pharmaceuticals (TLX) Announces First Patient Dosed in First-in-Human ZOLAR Trial of TLX300-CDx in Advanced Soft Tissue Sarcoma
-
Telix Pharmaceuticals (TLX) Announces FDA Approval of Gozellix
-
Telix Pharmaceuticals Limited (TLX) Reports FY results; offers guidance
-
Telix (TLX) announces UK approval of Illuccix
-
Trans-lux Corporation (TLX) Completes Acquisition of Next-Generation Therapeutic Assets and Innovative Biologics Technology Platform
-
UBS Starts Telix Pharmaceuticals Ltd (TLX) at Buy

